<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435133</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIO2015.1</org_study_id>
    <nct_id>NCT03435133</nct_id>
  </id_info>
  <brief_title>Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI</brief_title>
  <acronym>COMPARE</acronym>
  <official_title>Comparison of Prasugrel vs. Ticagrelor on Myocardial Injury in Revascularized ST Elevation Acute Myocardial Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AORTICA Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AORTICA Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to perform a randomized clinical trial comparing prasugrel vs.
      ticagrelor in 60 patients with ST elevation acute myocardial infarction (STEMI) undergoing
      primary percutaneous coronary intervention. The principal objective of the study would be
      analyzing the difference in myocardial infarction size measured by cardiac magnetic resonance
      at 6 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy consisting of aspirin and one of the P2Y12 receptor inhibitors is
      the mainstay of treatment for patients with ST elevation acute myocardial infarction
      undergoing primary percutaneous coronary intervention. Prasugrel or ticagrelor have actually
      shown to be superior to clopidogrel improving the prognosis of these patients. However, the
      industrial interest has avoided any direct comparison between these two antiplatelets.
      Comparison is of great interest considering that only ticagrelor has shown to significantly
      reduce mortality. As ticagrelor may exert off-target effects through adenosine-related
      mechanisms, the investigators aimed to investigate whether ticagrelor reduces myocardial
      injury to a greater extent than prasugrel in patients with revascularized STEMI.

      Patients with acute STEMI undergoing primary percutaneous coronary revascularization within 6
      hours of chest pain, will be randomized to (1) prasugrel (a 60 mg oral loading and a 10-mg
      dailiy maintenance dose) or to (2) ticagrelor (a 180 mg loading dose and a 90 mg twice daily
      maintenance dose). The predefined primary end point is infarct sieze on magnetic resonance
      imaging at the end of the study (6 months). Magnetic resonance will be performed at day 1,
      day 7 and moth 6. Platelet reactivity, biomarkers and clinical outcomes will also be assesed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac magnetic resonance imaging-assessed infarct size of left ventricular mass (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>up to two weeks</time_frame>
    <description>Cardiac magnetic resonance imaging-assessed infarct size of left ventricular mass (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial salvage index</measure>
    <time_frame>up to two weeks</time_frame>
    <description>Cardiac magnetic resonance imaging-assessed myocardial salvage index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction</measure>
    <time_frame>up to two weeks</time_frame>
    <description>Cardiac magnetic resonance imaging-assessed microvascular obstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of MACE defined as the composite of death, reinfarction, new-onset heart failure, or rehospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>60 mg oral bolus plus oral 10 mg once daily</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>180 mg oral bolus plus oral 90 mg every 12 hours daily</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older and equal or less than 75 years

          -  symptom onset within 12 hours before random assignment

          -  chest pain lasting more than 30 minutes

          -  ST-segment elevation of at least 0.1 mV in at least 2 limb leads, ST-segment elevation
             of at least 0.2 mV in 2 or more contiguous precordial leads, or left bundle-branch
             block or paced rhythm

          -  time from symptoms onset to randomization less than 6 hours

          -  no severe heart failure (Killip class &lt;3)

          -  informed, written consent

        Exclusion Criteria:

          -  history of myocardial infarction with Q wave

          -  history of surgical or percutaneous coronary revascularization

          -  cardiogenic shock, defined as a systolic blood pressure &lt;90 mm Hg with no response to
             fluid administration or &lt;100 mm Hg in patients with supportive treatment and no
             bradycardia

          -  history of stroke

          -  history of bronchial asthma

          -  symtomatic sinusal bradicardia or advance AV block

          -  history of hypersensitivity to aspirin, prasugrel or ticagrelor or contraindication to
             the doses established in the study

          -  patients pretreated with 600 mg of clopidogrel or more

          -  contraindication for the use of gadolinium during the magenitc resonance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro L Sanchez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Salamanca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro L Sanchez, MD</last_name>
    <phone>34923291100</phone>
    <phone_ext>55356</phone_ext>
    <email>pedrolsanchez@secardiologia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuria Sanchez Barbero</last_name>
    <phone>34923291100</phone>
    <phone_ext>55356</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pedro Dorado</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Dorado</last_name>
      <phone>3492329100</phone>
      <phone_ext>55369</phone_ext>
      <email>pedro.dorado@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AORTICA Group</investigator_affiliation>
    <investigator_full_name>Pedro L Sanchez</investigator_full_name>
    <investigator_title>Head of Cardiology, PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Primary angioplasty</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>STEMI</keyword>
  <keyword>cardiac magnetic resonance</keyword>
  <keyword>infarct size</keyword>
  <keyword>infarct injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

